Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer.

ABSTRACT:

Purpose

Growing numbers of clinical trials test the efficacy of radiotherapy (RT) plus immune checkpoint inhibitors (ICIs), but the number of irradiated sites is not uniform. We aimed to evaluate the efficacy of single-site RT plus immunotherapy in oligometastatic non-small cell lung cancer (NSCLC) with smaller disease burdens and low tumor heterogeneity.

Methods

We retrospectively identified oligometastatic NSCLC (< 4 metastatic sites) patients treated with PD-1 pathway inhibitors with or without RT to a single lesion in our institution between 2018 and 2020. The primary endpoints were the best objective response rate (ORR) and progression-free survival (PFS).

Results

Of the 152 patients enrolled, 93 and 59 were identified as the ICI alone group and the ICI plus RT g

SUBMITTER: Wang P 

PROVIDER: S-EPMC9015982 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature